🇺🇸 FDA
Patent

US 12385013

Differentiation of pancreatic endocrine cells

granted A61KA61K35/39

Quick answer

US patent 12385013 (Differentiation of pancreatic endocrine cells) held by Vertex Pharmaceuticals Incorporated expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K35/39